Aravive Biologics’ Treatment For Platinum-Resistant Recurrent Ovarian Cancer Receives Fast Track Designation

Aravive Biologics’ Treatment For Platinum-Resistant Recurrent Ovarian Cancer Receives Fast Track Designation

Source: 
CP Wire
snippet: 
  • Ph I trial showed reduction in biomarker associated with anti-tumor activity in animal models
  • There were no serious or dose-limiting adverse events in the Ph I trial
  • Aravive has a manufacturing collaboration with WuXi for AVB-S6-500